BFG
MRNA icon

Bleakley Financial Group’s Moderna MRNA Stock Holding History

Bleakley Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,934
Closed -$263K – 1091
2024
Q3 		$263K Sell
3,934
-907
-19% -$83.3K 0.01% 827
2024
Q2 		$575K Buy
4,841
+1,130
+30% +$143K 0.02% 564
2024
Q1 		$395K Buy
3,711
+362
+11% +$36.5K 0.01% 682
2023
Q4 		$333K Sell
3,349
-1,062
-24% -$89.3K 0.01% 704
2023
Q3 		$456K Buy
4,411
+497
+13% +$55.4K 0.02% 568
2023
Q2 		$476K Sell
3,914
-1,387
-26% -$185K 0.01% 601
2023
Q1 		$814K Sell
5,301
-317
-6% -$52.3K 0.03% 439
2022
Q4 		$1.01M Buy
+5,618
New +$919K 0.04% 371

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Bleakley Financial Group's MRNA Position: Q4 2024 in Review

Bleakley Financial Group sold out of Moderna (MRNA) in Q4 2024, closing a stake of 3,934 shares — an estimated $263K sold.

Bleakley Financial Group first reported a position in MRNA in Q4 2022 and held it in 8 quarters. The position peaked at $1.01M in Q4 2022. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Bleakley Financial Group reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 3,934 Moderna shares in Q4 2024, an estimated $263K.
  • Bleakley Financial Group first reported a position in Moderna in Q4 2022 and held it in 8 quarters.
  • Bleakley Financial Group's Moderna position peaked at $1.01M in Q4 2022.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Bleakley Financial Group's 13F filing for Q4 2024, filed 27 Jan 2025.